German biotechnology giant BioNTech, which gained global recognition for its vaccine developed during the COVID-19 pandemic, has been conducting extensive clinical trials to adapt this platform for cancer treatments. Personalized mRNA cancer vaccines, in particular, were seen as a potential solution to eliminate the risk of recurrence in cancer patients who had undergone tumor removal surgery but faced a high risk of the disease returning. Indeed, promising results recently shown by a personalized mRNA cancer vaccine developed by Merck and Moderna in melanoma patients had significantly raised expectations in this field. However, the latest news from BioNTech indicates that mRNA cancer vaccines may not achieve the same success in all cancer types.
BioNTech and its partner Genentech announced the termination of a mid-stage (Phase 2) clinical trial for an mRNA cancer vaccine conducted on high-risk colorectal cancer patients. The experimental vaccine, coded "Autogene cevumeran," was being tested to determine if it could extend the lifespan of high-risk patients who had undergone surgery and still had detectable cancer DNA in their blood. An independent monitoring committee's safety review found that the expected survival benefit would not be achieved in the treatment group.
The success achieved by Merck and Moderna in melanoma patients had also boosted BioNTech's shares. However, following this announcement, the company's shares on the US stock exchange fell by 7.5 percent.
Mortality Rate Among Vaccinated Patients in Trial May Have Been Higher
Upon examining the technical details behind the decision to halt the research, the situation appears to be more complex than a simple "failure." The monitoring committee identified a "numerical imbalance" in overall survival rates between the vaccinated group and the control group. Analysts and experts close to the matter suggest that this statement indicates that the mortality rates in the group that received the vaccine might have been higher compared to the control group.
In the clinical trial, high-risk patients who had completed surgery and three months of chemotherapy were given the vaccine, and its effectiveness in preventing recurrence was measured compared to standard follow-up. While this mechanism, which aims to introduce personalized mutations in cancer cells to the immune system, has shown successful results in "hot tumors" like melanoma, it has hit a significant wall in immunotherapy-resistant "cold tumors" such as colon and pancreatic cancers.
How Will This Process Affect Other Cancer Vaccine Studies?
This negative outcome has also raised questions about BioNTech's other mRNA projects. Although the company stated that its other mRNA vaccine study for pancreatic cancer patients, with results expected in 2031, would not be affected by this decision, analysts remain cautious. The similar biological resistance mechanisms of colon and pancreatic tumors weaken expectations for the future of the pancreatic study as well.
Of course, this does not mean that BioNTech will completely abandon mRNA cancer vaccines. On the contrary, the company aims to announce interim results for another mRNA study, coded BNT113, targeting head and neck cancers later this year. However, this latest development may lead BioNTech to shift its strategic focus to non-mRNA areas.
0 Comments: